This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sabin, A. B. Proc. natn. Acad. Sci. U.S.A. 89, 8852–8855 (1992).
Schwartz, D. H. et al. Lancet 342, 69–73 (1993).
Haigwood, N. L. et al. J. Virol. 66, 172–182 (1992).
Ada, G. L. in Fundamental Immunology 3rd edn (ed. Paul, W. E.) 1309–1352 (Raven, New York, 1993).
Cooney, E. L. et al. Lancet 337, 567–572 (1991).
Graham, B. S. et al. J. infect. Dis. 166, 244–252 (1992).
Cadoz, M. et al. Lancet 339, 1429–1432 (1992).
Cohen, J. Science 258, 1568–1570 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ada, G. Towards phase III trials for candidate vaccines. Nature 364, 489–490 (1993). https://doi.org/10.1038/364489a0
Issue Date:
DOI: https://doi.org/10.1038/364489a0
This article is cited by
-
Construction of virus-like particles exposing HIV-1 epitopes
Molecular Biology (2000)
-
Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant
European Journal of Clinical Microbiology and Infectious Diseases (1994)